Literature DB >> 7030952

Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure.

K Onoyama, H Hirakata, K Iseki, S Fujimi, T Omae, M Kobayashi, Y Kawahara.   

Abstract

Blood concentration and urinary excretion of captopril following 50 mg oral administration were determined by high-performance liquid chromatography in normal subjects and patients with chronic renal failure. In normal subjects, the maximum blood concentration of the free form of captopril was obtained within 1 hour and was not detectable after 6 hours; 41% of administered captopril was excreted into the urine as free form and metabolites within 2 hours, and 58% within 6 hours. In chronic renal failure patients with an average serum creatinine of 5.1 mg/dl, the absorption constant (Ka), maximum concentration (Cmax), and area under the blood concentration curve (AUC) were not significantly different from those in the normal subjects, but the elimination constant (Ke) and biological half-life (T1/2) showed a significant delay in the disappearance of captopril from the blood (p less than 0.01 respectively). The cumulative amount of urinary excretion of either free-form captopril or its' metabolites was significantly decreased at 2, 4, and 6 hours in chronic renal failure patients (p less than 0.01 or less, respectively). Impairment of kidney function is suggested to be an important factor in the promotion of blood retention of captopril.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7030952     DOI: 10.1161/01.hyp.3.4.456

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

Authors:  Rana R McKay; Gustavo E Rodriguez; Xun Lin; Marina D Kaymakcalan; Ole-Petter R Hamnvik; Venkata S Sabbisetti; Rupal S Bhatt; Ronit Simantov; Toni K Choueiri
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency.

Authors:  B C Campbell; A N Shepherd; H L Elliott; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 4.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

5.  Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

Authors:  C Richer; B Giroux; P F Plouin; B Maarek; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 7.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

8.  Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.

Authors:  J F Giudicelli; M Chaignon; C Richer; B Giroux; J Guedon
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 9.  Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.

Authors:  K L Duchin; D N McKinstry; A I Cohen; B H Migdalof
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.

Authors:  S H Kubo; R J Cody
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.